Skip to content

max iv

Mining the secrets of lipid nanoparticles using research infrastructures

Robert Schnell is a scientist at Karolinska Institute focusing on development of novel antibiotic candidates. He has used both SciLifeLab and MAX IV laboratory infrastructures in a multifaceted project addressing the problem of infectious diseases in the context of the silent pandemic of antimicrobial resistance (AMR). 

The value of attending a course

Robert Schnell is a scientist at Karolinska Institute focusing on development of novel antibiotic candidates. He has used both SciLifeLab and MAX IV laboratory infrastructures in a multifaceted project addressing the problem of infectious diseases in the context of the silent pandemic of antimicrobial resistance (AMR). 

Antibiotic research pushed forward by use of large infrastructures

Robert Schnell is a scientist at Karolinska Institute focusing on development of novel antibiotic candidates. He has used both SciLifeLab and MAX IV laboratory infrastructures in a multifaceted project addressing the problem of infectious diseases in the context of the silent pandemic of antimicrobial resistance (AMR).